Literature DB >> 10961588

Exclusion of linkage of Crohn's disease to previously reported regions on chromosomes 12, 7, and 3 in the Belgian population indicates genetic heterogeneity.

S Vermeire1, M Peeters, R Vlietinck, M Parkes, J Satsangi, D Jewell, P Rutgeerts.   

Abstract

Susceptibility to inflammatory bowel disease (IBD) is significantly determined by genetic factors. Linkage data from genome-wide searches have identified regions on chromosomes 16, 12, 7, and 3. Our goal was to replicate these four regions in a Belgian population of IBD families. Fifty-four IBD families were studied (47 with Crohn's disease [CD] and 7 with mixed CD and ulcerative colitis, containing 79 affected sibpairs (68 CD only, 11 mixed) for the regions previously implicated to chromosomes 16, 12, 7, and 3. In this study, no evidence for linkage was found on any of the four chromosomal regions studied for either the whole IBD dataset or the CD subgroup. The multipoint maximum logarithm of odds scores were less than 0.7 for all four regions. Exclusion mapping could significantly exclude chromosomes 3, 7, and 12. Despite earlier findings, we could significantly exclude linkage of CD with previously reported regions on chromosomes 12, 7, and 3, and could not find evidence for linkage to chromosome 16. It is important to report these findings in light of the genetic heterogeneity of IBD. A genome-wide search on a larger group of affected siblings is being analyzed to detect other possible susceptibility loci in the Belgian population.

Entities:  

Mesh:

Year:  2000        PMID: 10961588     DOI: 10.1097/00054725-200008000-00002

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  7 in total

1.  International collaboration provides convincing linkage replication in complex disease through analysis of a large pooled data set: Crohn disease and chromosome 16.

Authors:  J Cavanaugh
Journal:  Am J Hum Genet       Date:  2001-04-12       Impact factor: 11.025

2.  The IBD2 locus shows linkage heterogeneity between ulcerative colitis and Crohn disease.

Authors:  M Parkes; M M Barmada; J Satsangi; D E Weeks; D P Jewell; R H Duerr
Journal:  Am J Hum Genet       Date:  2000-11-10       Impact factor: 11.025

3.  Signal transducer and activator of transcription 6 gene G2964A polymorphism and inflammatory bowel disease.

Authors:  B Xia; J B A Crusius; J Wu; A Zwiers; A A van Bodegraven; A S Peña
Journal:  Clin Exp Immunol       Date:  2003-03       Impact factor: 4.330

Review 4.  Progress in searching for susceptibility gene for inflammatory bowel disease by positional cloning.

Authors:  Chang-Qing Zheng; Gang-Zheng Hu; Zhao-Shu Zeng; Lian-Jie Lin; Gin-Ge Gu
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

5.  Genome wide scan in a Flemish inflammatory bowel disease population: support for the IBD4 locus, population heterogeneity, and epistasis.

Authors:  S Vermeire; P Rutgeerts; K Van Steen; S Joossens; G Claessens; M Pierik; M Peeters; R Vlietinck
Journal:  Gut       Date:  2004-07       Impact factor: 23.059

Review 6.  Genetic evidence supporting the association of protease and protease inhibitor genes with inflammatory bowel disease: a systematic review.

Authors:  Isabelle Cleynen; Peter Jüni; Geertruida E Bekkering; Eveline Nüesch; Camila T Mendes; Stefanie Schmied; Stefan Wyder; Eliane Kellen; Peter M Villiger; Paul Rutgeerts; Séverine Vermeire; Daniel Lottaz
Journal:  PLoS One       Date:  2011-09-08       Impact factor: 3.240

7.  Analysis of germline GLI1 variation implicates hedgehog signalling in the regulation of intestinal inflammatory pathways.

Authors:  Charlie W Lees; William J Zacharias; Mark Tremelling; Colin L Noble; Elaine R Nimmo; Albert Tenesa; Jennine Cornelius; Leif Torkvist; John Kao; Susan Farrington; Hazel E Drummond; Gwo-Tzer Ho; Ian D R Arnott; Henry D Appelman; Lauri Diehl; Harry Campbell; Malcolm G Dunlop; Miles Parkes; Sarah E M Howie; Deborah L Gumucio; Jack Satsangi
Journal:  PLoS Med       Date:  2008-12-09       Impact factor: 11.069

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.